These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies]. Belaiche J; Louis E Rev Med Liege; 2000 Sep; 55(9):827-32. PubMed ID: 11105596 [TBL] [Abstract][Full Text] [Related]
6. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Keating GM; Perry CM BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485 [TBL] [Abstract][Full Text] [Related]
7. Infliximab (Remicade), a new biological treatment for Crohn's disease. D'Haens GR Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab for the treatment of Crohn's disease. Devlin SM; Panaccione R Expert Opin Biol Ther; 2008 Jul; 8(7):1011-9. PubMed ID: 18549330 [TBL] [Abstract][Full Text] [Related]
9. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Bell S; Kamm MA Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696 [No Abstract] [Full Text] [Related]
10. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016 [TBL] [Abstract][Full Text] [Related]
11. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. D'haens G; Van Deventer S; Van Hogezand R; Chalmers D; Kothe C; Baert F; Braakman T; Schaible T; Geboes K; Rutgeerts P Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center]. Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390 [TBL] [Abstract][Full Text] [Related]
15. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255 [TBL] [Abstract][Full Text] [Related]
16. Transcending conventional therapies: the role of biologic and other novel therapies. Sandborn WJ Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043 [TBL] [Abstract][Full Text] [Related]
17. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for). Shanahan F Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074 [No Abstract] [Full Text] [Related]
18. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252 [TBL] [Abstract][Full Text] [Related]
19. TNF-alpha antagonists for the treatment of Crohn's disease. Kam LY; Targan SR Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506 [TBL] [Abstract][Full Text] [Related]
20. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. van Deventer SJ Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]